20 October 2023
20 October 2023
There are currently many unmet needs for Parkinson’s patients but several pipeline drugs are looking to address these.
Janssen reported data on Tremfya from a Phase IIIb trial that included psoriasis patients and investigators from diverse backgrounds.
The safety profile of subcutaneous nivolumab was in line with the IV dose.
Clinical activity of R-2487 will be assessed by measuring improvement in rheumatoid arthritis disease severity.
The company plans to initiate the Phase II trial of anti-IL-6 antibody in atherosclerotic cardiovascular disease in 2024.
The study will focus on recruiting participants from groups across the UK and France.
In preclinical urothelial cancer animal models, oral doses of FX-909 demonstrated strong anti-tumour activity.
The Genentech-sponsored trial plans to enrol 260 subjects with resected PDAC.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
